Cannabis Science Company Profile (OTCMKTS:CBIS)

About Cannabis Science (OTCMKTS:CBIS)

Cannabis Science logoCannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CBIS
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $158.43 million
  • Outstanding Shares: 2,390,305,000
Average Prices:
  • 50 Day Moving Avg: $0.07
  • 200 Day Moving Avg: $0.07
  • 52 Week Range: $0.01 - $0.14
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00000
Sales & Book Value:
  • Annual Revenue: $9,263.00
  • Price / Sales: 17,103.47
  • Book Value: $0.00 per share
  • Price / Book: -66.28
  • EBIDTA: ($7,570,000.00)
  • Average Volume: 19.15 million shs.

Frequently Asked Questions for Cannabis Science (OTCMKTS:CBIS)

What is Cannabis Science's stock symbol?

Cannabis Science trades on the OTCMKTS under the ticker symbol "CBIS."

How were Cannabis Science's earnings last quarter?

Cannabis Science Inc (OTCMKTS:CBIS) announced its quarterly earnings data on Tuesday, July, 28th. The company reported $0.00 earnings per share for the quarter. View Cannabis Science's Earnings History.

Who are some of Cannabis Science's key competitors?

How do I buy Cannabis Science stock?

Shares of Cannabis Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cannabis Science stock cost?

One share of Cannabis Science stock can currently be purchased for approximately $0.07.

Analyst Ratings

Consensus Ratings for Cannabis Science (OTCMKTS:CBIS) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cannabis Science (OTCMKTS:CBIS)
No equities research coverage for this company has been tracked by


Earnings History for Cannabis Science (OTCMKTS:CBIS)
Earnings by Quarter for Cannabis Science (OTCMKTS:CBIS)
Earnings History by Quarter for Cannabis Science (OTCMKTS:CBIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2015Q3 2016$0.00ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cannabis Science (OTCMKTS:CBIS)

No earnings estimates for this company have been tracked by


Dividend History for Cannabis Science (OTCMKTS:CBIS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cannabis Science (OTCMKTS:CBIS)
Insider Trades by Quarter for Cannabis Science (OTCMKTS:CBIS)
Insider Trades by Quarter for Cannabis Science (OTCMKTS:CBIS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Robert James KaneCOOSell2,000,000$0.07$140,000.00View SEC Filing  
10/19/2016Robert James KaneCOOSell4,000,000$0.04$160,000.00View SEC Filing  
10/14/2016Robert James KaneCFOSell1,389,577$0.02$27,791.54View SEC Filing  
10/10/2016Robert James KaneCFOSell1,783,475$0.02$35,669.50View SEC Filing  
9/13/2016Robert James KaneCFOSell2,000,000$0.01$20,000.00View SEC Filing  
5/18/2016Robert James KaneCFOSell503,345$0.02$10,066.90View SEC Filing  
5/6/2016Robert James KaneCFOSell300,000$0.02$6,000.00View SEC Filing  
3/31/2016Chad Steven JohnsonCOOSell500,000$0.02$10,000.00View SEC Filing  
3/29/2016Chad Steven JohnsonCOOSell2,402,000$0.02$48,040.00View SEC Filing  
3/21/2016Chad Steven JohnsonCOOSell483,852$0.02$9,677.04View SEC Filing  
3/3/2016Chad Steven JohnsonCOOSell2,188,334$0.01$21,883.34View SEC Filing  
2/29/2016Chad Steven JohnsonCOOSell4,370,000$0.01$43,700.00View SEC Filing  
2/19/2016Chad Steven JohnsonCOOSell1,765,300$0.01$17,653.00View SEC Filing  
12/11/2015Chad Steven JohnsonCOOSell1,646,142$0.02$32,922.84View SEC Filing  
12/3/2015Chad Steven JohnsonCOOSell769,986$0.02$15,399.72View SEC Filing  
12/2/2015Chad Steven JohnsonCOOSell1,852,239$0.02$37,044.78View SEC Filing  
8/19/2015Chad Steven JohnsonCOOSell6,500,000$0.03$195,000.00View SEC Filing  
6/9/2015Chad Steven JohnsonCOOSell1,063,575$0.03$31,907.25View SEC Filing  
4/29/2015Chad Steven JohnsonCOOSell921,333$0.04$36,853.32View SEC Filing  
3/27/2015Chad Steven JohnsonCOOSell1,400,000$0.04$56,000.00View SEC Filing  
3/19/2015Chad Steven JohnsonCOOSell1,262,691$0.05$63,134.55View SEC Filing  
2/4/2015Chad Steven JohnsonCOOSell1,809,914$0.06$108,594.84View SEC Filing  
1/20/2015Chad Steven JohnsonCOOSell255,000$0.07$17,850.00View SEC Filing  
1/14/2015Dh BrayCEOSell1,260,750$0.06$75,645.00View SEC Filing  
1/5/2015Chad Steven JohnsonCOOSell1,600,000$0.07$112,000.00View SEC Filing  
11/20/2014Chad Steven JohnsonCOOSell433,990$0.07$30,379.30View SEC Filing  
11/14/2014Chad Steven JohnsonCOOSell251,110$0.06$15,066.60View SEC Filing  
11/3/2014Chad Steven JohnsonCOOSell400,000$0.09$36,000.00View SEC Filing  
10/31/2014Chad Steven JohnsonCOOSell750,000$0.08$60,000.00View SEC Filing  
2/13/2014Robert MelamedeMajor ShareholderSell425,800$0.17$72,386.00View SEC Filing  
2/11/2014Robert MelamedeMajor ShareholderSell779,200$0.19$148,048.00View SEC Filing  
2/6/2014Robert MelamedeMajor ShareholderSell473,300$0.25$118,325.00View SEC Filing  
2/4/2014Robert MelamedeMajor ShareholderSell659,700$0.19$125,343.00View SEC Filing  
1/30/2014Robert MelamedeMajor ShareholderSell600,200$0.19$114,038.00View SEC Filing  
1/27/2014Robert MelamedeMajor ShareholderSell525,000$0.14$73,500.00View SEC Filing  
1/22/2014Robert MelamedeMajor ShareholderSell476,500$0.11$52,415.00View SEC Filing  
1/16/2014Robert MelamedeMajor ShareholderSell425,800$0.10$42,580.00View SEC Filing  
1/13/2014Robert MelamedeMajor ShareholderSell248,800$0.12$29,856.00View SEC Filing  
1/9/2014Robert MelamedeMajor ShareholderSell170,200$0.13$22,126.00View SEC Filing  
1/7/2014Robert MelamedeMajor ShareholderSell132,200$0.07$9,254.00View SEC Filing  
1/3/2014Robert MelamedeMajor ShareholderSell83,300$0.07$5,831.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cannabis Science (OTCMKTS:CBIS)
Latest Headlines for Cannabis Science (OTCMKTS:CBIS)
DateHeadline logoCannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts - May 26 at 4:36 PM logoCannabis Science Releases First Test Batch of Suppositories to Aid Self-Medicating Patients That Require Alternative Delivery Methods With Severe Pain and Symptoms Related to Cancers, Anxiety, and Insomnia - May 11 at 4:46 PM logo2017 Cannabis Market Developments - May 4 at 4:19 PM logoCannabis Science Senior Executives Chair Special Sessions and Deliver a Keynote Speech at the Global Health Catalyst Summit at Harvard Medical School - May 2 at 7:56 PM logoCBIS Stock: Potent Potential or Diluted Dud? - May 1 at 4:08 PM logoCannabis Science Senior Executives Arrive at the Global Health Catalyst Summit at Harvard Medical School - April 29 at 4:47 PM logoCannabis Science Selects Influential Southern California Financial Firm as the Lead to Raise the Proposed 25 Million USD in Expansion Capital and Boost its Industry Footprint - April 27 at 4:35 PM logoCannabis Science 2017 Black Tie Gala for Cannabinoid Research Targeting Critical Ailments, Testimonials, Celebrity Interests, New Partnerships, and Loyalty Gift to Shareholders - April 25 at 12:21 PM logoCannabis Science Continues Expansions as it Negotiates to Acquire Two Medical Marijuana Dispensaries in Los Angeles, California; The Company Expects to Sign Closing Documents Shortly - April 21 at 4:14 PM logoCannabis Science Issues First Quarter Update and Celebrates 4/20 With Unprecedented Revenue Growth Projections and Sustainable Equity Value Looking Forward to More Quarterly Growth and Progress Reports - April 20 at 4:19 PM logoCannabis Science Senior Executives Set to Present Drug Development Initiatives to Key Stakeholders Around the World at the Upcoming Global Health Catalyst Summit at Harvard Medical School Next Week, April 28 - 30th 2017 - April 19 at 6:03 PM logoCBIS Pushes Up the Seeding Schedule Next Month to 350 Acres Set to Include Additional 100 Acres in Minden Carson Valley Property Along with the San Joaquin Valley Property for its Industrial Commercial Hemp Grow Initiatives - April 17 at 4:02 PM logoCBIS and RCDU Sign Another Large California Cultivation Land Deal for Two Hundred and Fifty Acres, Scheduled to be Seeded all at Once for Maximum Harvest and Research Production - April 13 at 4:17 PM logoCannabis Science To File Offering Memorandum for 25 Million USD in Expansion Capital - Yahoo Finance - April 7 at 9:11 PM logoCannabis Science To File Offering Memorandum for 25 Million USD in Expansion Capital - April 7 at 4:10 PM logoCBIS Subsidiary, Cannabis Science Europe GmbH, Acquires … - April 7 at 8:51 AM logoCannabis Science's Acquisition Raises More Questions Than Answers - April 7 at 8:51 AM logoCBIS Subsidiary, Cannabis Science Europe GmbH, Acquires Majority Shares of German Bio Med GmbH Jinvator to Facilitate European Expansions, New Products, and Additional Clinical Studies - April 7 at 8:51 AM logoCBIS Appoints Leader of Global Health Information Julia Royall to Its Scientific Advisory Board - March 30 at 4:35 PM logoCBIS Ramps Up Production and Releases More New Products to Meet the Substantial Requests From Self-Medicating Patients Across the Country as it Highlights Moonlight Cannabis as its Newest Spotlight Dispensary for the Month of April 2017 - March 27 at 4:07 PM logoCannabis Science Receives Delivery Notifications for First Greenhouse Orders as it Prepares Cannabinoid Observational and Clinical Studies Targeting Several Critical Ailments - March 8 at 4:54 PM logoCannabis Science Senior Executives to Co-Chair... - March 2 at 4:22 PM logoCannabis Science Senior Executives to Co-Chair Special Session and Deliver a Keynote Speech at the Global Health Catalyst Summit at Harvard Medical School - March 2 at 4:22 PM logoIgnore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks - March 2 at 4:22 PM logoCannabis CBD Infused Products Grow in Popularity Along With Newest Medicinal Applications and Uses - February 28 at 9:15 AM logoCannabis Science Announces Update on Proposed DPI Inhalation Device, CBD Infused Pain Patch, and Extends ... - Benzinga - February 25 at 2:22 AM logoCannabis Science Announces Update on Proposed DPI Inhalation Device, CBD Infused Pain Patch, and Extends Praise for President Trump's Support of Medical Cannabis, Nationwide - February 24 at 12:43 PM logoLegal Marijuana Industry Fueling Higher Standard of Production and Preservation for Cannabis Based Products - PR Newswire (press release) - February 21 at 1:50 PM logoCrown Baus Capital Corp. Acquires 100-Acre Investment Participation in Cannabis Science's California and Nevada Property and Drug Development Projects - February 17 at 6:00 PM logoCrown Baus Team Negotiates Investment Opportunity with Cannabis Science (CBIS) for Stake in California Property Development Projects and the Nevada Cannabinoid Drug Production Facilities in Douglas County, Nevada - February 7 at 5:15 PM Cannabis-Infused Products Boosting Legal Marijuana Industry Revenue Streams - February 3 at 2:39 AM logoMarijuana Industry Pushing Toward Federal Acceptance, Expanded Research in 2017 - February 1 at 4:24 PM logoCannabis Science Distributors Sells Out of Initial Test Batch of CBIS Metered Dose Inhalers (MDI), Notes Consumer ... - MarketWatch - January 26 at 5:01 PM logoCANNABIS SCIENCE INC - January 25 at 10:17 PM logoCannabis Science Distributors Sells Out of Initial Test Batch of CBIS Metered Dose Inhalers (MDI), Notes Consumer High-Demand for the CBIS Inhaler in California - January 25 at 5:14 PM



Cannabis Science (CBIS) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff